Veracyte Director Receives 9,321 RSU Grant, Holds 73,919 Total Shares

Veracyte Director Robert S. Epstein received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Veracyte Director Robert S. Epstein received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025. Following this transaction, Epstein's direct ownership increased to 73,919 shares.

Key terms of the RSU award:

Vesting occurs in full on the first anniversary of the grant date
Alternative vesting trigger: immediately prior to the company's next annual meeting of stockholders, if earlier
Accelerated vesting provision in the event of a change in control
Grant price: $0

The Form 4 was filed on June 23, 2025, within the required reporting window. The transaction was executed under transaction code 'A' indicating an acquisition of securities. This equity grant appears to be part of Veracyte's director compensation program.

Insider Trade Summary

Grant/Award: 9,321 shares

Grant/Award 1 txn

Insider EPSTEIN ROBERT S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	9,321	$0.00	$0.00

Holdings After Transaction: Common Stock — 73,919 shares (Direct)

Footnotes (1)

F1. Restricted stock units awarded on June 18, 2025 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many VCYT shares did Robert Epstein acquire on June 18, 2025?

Robert Epstein acquired 9,321 shares of Veracyte (VCYT) common stock on June 18, 2025 in the form of restricted stock units (RSUs).

What is the vesting schedule for VCYT's RSUs granted to director Robert Epstein?

The RSUs vest in full on either the first anniversary of the grant date (June 18, 2026) or immediately prior to Veracyte's next annual meeting of stockholders, whichever comes earlier. Additionally, the RSUs will fully vest if there is a change in control of the company.

How many VCYT shares does Robert Epstein own after the June 18, 2025 transaction?

Following the RSU grant transaction, Robert Epstein beneficially owns 73,919 shares of Veracyte (VCYT) stock directly.

What is Robert Epstein's role at VCYT according to the Form 4?

According to the Form 4 filing, Robert Epstein serves as a Director of Veracyte, Inc. (VCYT).

What was the purchase price of VCYT shares in Epstein's June 18, 2025 transaction?

The RSUs were granted at $0 cost to Robert Epstein, as they represent equity compensation for his service as a director of Veracyte.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2025 - 04:10 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EPSTEIN ROBERT S

(Last)

(First)

(Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/18/2025		A⁽¹⁾		9,321	A	$0	73,919	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Restricted stock units awarded on June 18, 2025 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR